The contract at issue is mainly for people with health insurance through their employers. Cigna's Medicare Advantage plans, ...

The drug, vepdegestrant, failed to meaningfully delay cancer progression for all patients enrolled in the study but met its goals for a subset who have a specific genetic mutation ...